MedTrace Logo

DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001

NCT04290676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 527

Last updated 2021-05-26

Study results available
· View outcomes & findings →

Summary

Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.

Conditions

  • Cataract

Interventions

DRUG

DEXYCU (dexamethasone intraocular suspension) 9%.

DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).

Sponsors & Collaborators

  • EyePoint Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Dario Paggiarino, MD · Senior Vice President, Chief Medical Officer, EyePoint Pharmaceuticals

  • Keyur Patel, PharmD · Vice President, Medical Affairs, EyePoint Pharmaceuticals

  • Flavio Leonin, Jr., MD · Senior Manager, Clinical Affairs, EyePoint Pharmaceuticals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-13
Primary Completion
2020-05-01
Completion
2020-05-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04290676 on ClinicalTrials.gov